PCSK9 and stroke disorder: An earlier meta-analytic study of 67 RCTs including 259,429 participants with PCSK9 inhibitors plus statin confirmed the significantly reduced risk of non-fatal MI (RR 0.82; 95% CI 0.72–0.93, p = 0.003) or stroke (RR 0.74; 95% CI 0.65–0.85, p < 0.001) [71].